68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

This study is evaluating a new type of imaging scan using a radioactive tracer called 68Ga-HA-DOTATATE to detect and map tumors that have a special protein on their surface (somatostatin receptors). These include neuroendocrine tumors, pheochromocytomas, paragangliomas, and certain brain tumors. **You may be eligible if...** - You have a known or suspected somatostatin receptor-positive tumor (such as neuroendocrine tumors of the gut, pancreas, lungs, pheochromocytoma, paraganglioma, medullary thyroid cancer, meningioma, or medulloblastoma) - You have had a standard CT or MRI scan within the past 6 months - You are able to give written consent **You may NOT be eligible if...** - You weigh more than 225 kg (the weight limit of the scanner) - You cannot lie still or have severe claustrophobia - You have had an allergic reaction to DOTATATE or similar medications (somatostatin analogues) - You do not have IV (intravenous) access - You have a serious medical condition that would interfere with the scan Talk to your doctor to see if this trial is right for you.